What are Addex Therapeutics Ltd’s latest earnings?

As of the latest earnings, Addex reported a revenue of CHF71,055, which missed the market's estimated figures. The company's EPS was -0.01556 as of the last quarter.

How is Addex positioned in the biotechnology market?

Addex primarily focuses on developing treatments for CNS disorders and has partnerships with established pharmaceutical companies like Janssen Pharmaceuticals, which solidify its market position.

What are the key financial indicators for Addex Therapeutics?

Key financial indicators include a market capitalization of CHF9.93 million, a debt-to-equity ratio of 0.0053, and a current trading price around CHF0.0578, aligning closely with technical averages.

How does Meyka AI contribute to analyzing stocks like ADXN.SW?

Meyka AI provides AI-powered insights and real-time financial data to evaluate stocks like ADXN.SW, offering investors detailed market analysis and predictions.

What should investors watch for in Addex's financials?

Investors should monitor upcoming earnings announcements and partnership developments, which could significantly impact the company's financial trajectory. Stock prices can fluctuate based on market conditions, economic factors, and company-specific events.

CH Stocks

Addex Therapeutics Ltd (ADXN.SW): Navigating the Biotech Landscape with Strategic Developments and Earnings Insights

ByHuzaifa Zahoor December 2, 2025December 2, 2025

Addex Therapeutics Ltd (ADXN.SW) has emerged as a notable player in the Swiss biotech market, with its latest market price noted at CHF0.0578, reflecting a 3.21% increase. This analysis provides an exploration into Addex’s financial performance and strategic position in the healthcare sector.